The global radiopharmaceuticals in nuclear medicine market is expected to reach a value of US$ 6,700.5 million by 2022 and exhibit a CAGR of 8.0% from 2023 to 2030, according to a new report. The report provides detailed insights into the market, including key players, market dynamics, drivers, and segments. It also offers a comprehensive analysis of the competitive landscape and growth strategies. The major players in the market include Progenics Pharmaceuticals, Curium Pharma, Lantheus Holdings, and Cardinal Health, among others. The report aims to provide valuable information to stakeholders to help them make informed investment decisions.
Thu, 03 Aug 2023 11:49:32 GMT | Digital Journal